Citigroup
EVFM

Citigroup’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Citigroup’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-736,406
Closed -$832K – 6695
2022
Q2 		$832K Buy
736,406
+736,239
+440,862% +$1.21M ﹤0.01% 2818
2022
Q1 		$1K Buy
+167
New +$1.05K ﹤0.01% 6263
2021
Q3 		– Sell
-67
Closed -$1K – 6500
2021
Q2 		$1K Sell
67
-5,169
-99% -$98K ﹤0.01% 6082
2021
Q1 		$137K Buy
5,236
+4,262
+438% +$194K ﹤0.01% 4220
2020
Q4 		$35K Buy
974
+668
+218% +$24.2K ﹤0.01% 6298
2020
Q3 		$11K Sell
306
-222
-42% -$9.65K ﹤0.01% 6586
2020
Q2 		$22K Buy
528
+260
+97% +$17.5K ﹤0.01% 6561
2020
Q1 		$21K Buy
268
+79
+42% +$6.32K ﹤0.01% 6672
2019
Q4 		$18K Buy
189
+90
+91% +$7.59K ﹤0.01% 6988
2019
Q3 		$8K Sell
99
-164
-62% -$12.6K ﹤0.01% 7194
2019
Q2 		$26K Buy
+263
New +$20.4K ﹤0.01% 6955
2016
Q2 		– Sell
-1
Closed – – 7578
2016
Q1 		$0 Buy
+1
New +$77 ﹤0.01% 7890

Other funds holding EVFM

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Citigroup's EVFM Position: Q3 2022 in Review

Citigroup sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 736,406 shares — an estimated $832K sold.

Citigroup first reported a position in EVFM in Q1 2016 and held it in 12 quarters. The position peaked at $832K in Q2 2022. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

  • Citigroup reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 736,406 Evofem Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $832K.
  • Citigroup first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2016 and held it in 12 quarters.
  • Citigroup's Evofem Biosciences, Inc. Common Stock position peaked at $832K in Q2 2022.
  • 8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.